Differences of clinical data between ET and early PMF in the Vienna cohort of patients
| . | ET (126 patients) . | Early PMF (81 patients) . | Z value . | P (2-tailed)* . |
|---|---|---|---|---|
| Age, y | 58.1 (18.7-85.4) | 64.9 (26.9-88.1) | −2.084 | .037 |
| Hemoglobin, g/dL | 14.2 (11.4-17.3) | 13.2 (7.9-16.6) | −2.622 | .009 |
| Hematocrit, % | 42.5 (33.0-52.0) | 39.6 (25.0-51.0) | −2.930 | .003 |
| Leukocytes, × 109/L | 8.8 (4.0-21.8) | 10.0 (5.5-24.5) | −2.827 | .005 |
| Erythroblasts, % | 0 (0-0) | 0 (0-2) | −3.293 | .001 |
| Myeloblasts, % | 0 (0-1) | 0 (0-2) | −3.163 | .002 |
| Platelets, × 109/L | 758 (326-2204) | 784 (112-1960) | −0.198 | .843 |
| Spleen size, cm† | 0 (0-11) | 1.5 (0-15) | −5.388 | < .001 |
| LDH, U/L | 212 (118-534) | 321 (164-667) | −7.456 | < .001 |
| . | ET (126 patients) . | Early PMF (81 patients) . | Z value . | P (2-tailed)* . |
|---|---|---|---|---|
| Age, y | 58.1 (18.7-85.4) | 64.9 (26.9-88.1) | −2.084 | .037 |
| Hemoglobin, g/dL | 14.2 (11.4-17.3) | 13.2 (7.9-16.6) | −2.622 | .009 |
| Hematocrit, % | 42.5 (33.0-52.0) | 39.6 (25.0-51.0) | −2.930 | .003 |
| Leukocytes, × 109/L | 8.8 (4.0-21.8) | 10.0 (5.5-24.5) | −2.827 | .005 |
| Erythroblasts, % | 0 (0-0) | 0 (0-2) | −3.293 | .001 |
| Myeloblasts, % | 0 (0-1) | 0 (0-2) | −3.163 | .002 |
| Platelets, × 109/L | 758 (326-2204) | 784 (112-1960) | −0.198 | .843 |
| Spleen size, cm† | 0 (0-11) | 1.5 (0-15) | −5.388 | < .001 |
| LDH, U/L | 212 (118-534) | 321 (164-667) | −7.456 | < .001 |